MCKESSON CORP's ticker is MCK and the CUSIP is 58155Q103. A total of 1,590 filers reported holding MCKESSON CORP in Q2 2024. The put-call ratio across all filers is 1.04 and the average weighting 0.3%.
About MCKESSON CORP
McKesson Corp is a leading healthcare services and information technology company that provides innovative solutions to improve patient care and reduce healthcare costs. The company operates in three segments: pharmaceutical distribution, technology solutions, and medical-surgical solutions.
In the pharmaceutical distribution segment, McKesson is the largest distributor of pharmaceuticals and medical supplies in North America. The company's technology solutions segment provides software and analytics to help healthcare providers improve patient outcomes and reduce costs. The medical-surgical solutions segment offers medical-surgical supplies and equipment to healthcare providers.
McKesson has a strong financial position with a market capitalization of over $30 billion and a revenue of $231 billion in 2020. The company has a diverse customer base, including hospitals, pharmacies, and healthcare providers.
McKesson has been actively involved in the fight against the COVID-19 pandemic. The company has been working with the government and healthcare providers to distribute vaccines and medical supplies to combat the virus. McKesson has also been providing support to healthcare providers by offering telehealth solutions and other digital tools to help them manage patient care remotely.
In conclusion, McKesson Corp is a leading healthcare services and information technology company that is committed to improving patient care and reducing healthcare costs. With its strong financial position and diverse customer base, the company is well-positioned to continue its growth and innovation in the healthcare industry.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $363,857 | +9.3% | 623 | +0.5% | 0.05% | +6.1% |
| Q1 2024 | $332,847 | +42.9% | 620 | -55.7% | 0.05% | -40.2% |
| Q3 2016 | $233,000 | -10.7% | 1,400 | 0.0% | 0.08% | -14.6% |
| Q2 2016 | $261,000 | +18.6% | 1,400 | 0.0% | 0.10% | +24.7% |
| Q1 2016 | $220,000 | -62.8% | 1,400 | -53.3% | 0.08% | -62.1% |
| Q4 2015 | $592,000 | +12.8% | 3,000 | +5.7% | 0.20% | -6.0% |
| Q3 2015 | $525,000 | -26.7% | 2,837 | -11.0% | 0.22% | -19.4% |
| Q2 2015 | $716,000 | -2.2% | 3,187 | -1.5% | 0.27% | 0.0% |
| Q1 2015 | $732,000 | -3.0% | 3,237 | -11.0% | 0.27% | -5.0% |
| Q4 2014 | $755,000 | +1.1% | 3,637 | -5.2% | 0.28% | 0.0% |
| Q3 2014 | $747,000 | +5.5% | 3,837 | +1.0% | 0.28% | +2.2% |
| Q2 2014 | $708,000 | -99.9% | 3,800 | -18.3% | 0.28% | -20.5% |
| Q1 2014 | $821,051,000 | +84024.1% | 4,650 | -23.1% | 0.35% | -15.6% |
| Q4 2013 | $976,000 | +14.0% | 6,050 | -9.3% | 0.41% | +2.8% |
| Q3 2013 | $856,000 | +8.8% | 6,670 | -2.9% | 0.40% | -5.9% |
| Q2 2013 | $787,000 | – | 6,870 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARISTOTLE FUND, L.P. | 105,000 | $14,747,000 | 11.49% |
| NORTH RUN CAPITAL, LP | 235,000 | $33,006,000 | 10.08% |
| Tavio Capital LLC | 73,112 | $10,269,000 | 9.69% |
| HealthInvest Partners AB | 57,000 | $8,006,000 | 7.38% |
| TAYLOR ASSET MANAGEMENT INC | 170,100 | $23,891,000 | 6.97% |
| AXON CAPITAL LP | 68,181 | $9,576,000 | 5.75% |
| GOBI CAPITAL LLC | 43,195 | $6,067,000 | 5.55% |
| TRENT CAPITAL MANAGEMENT INC /NC/ | 31,813 | $4,468,000 | 4.99% |
| Vulcan Value Partners, LLC | 3,461,194 | $486,125,000 | 4.33% |
| Par Capital Management | 2,000,650 | $280,991,000 | 3.67% |